Compare Air Products & Chemicals, Inc. (APD) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Air Products & Chemicals, Inc. vs Novavax Inc — how do they compare? Air Products & Chemicals, Inc. trades at $308.56 (market cap $68.63B), while Novavax Inc trades at $7.96 (market cap $1.30B). The key difference: Air Products & Chemicals, Inc. is far larger — about 52.8× Novavax Inc's market cap, and Air Products & Chemicals, Inc. pays a 2.35% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| APD | NVAX | |
|---|---|---|
Market Cap | $68.63B | $1.30B |
Sector | Basic Materials | Health |
52-Week High | $314.19 | $11.19 |
52-Week Low | $230.42 | $6.22 |
Enterprise Value | $85.80B | $879.40M |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Air Products and Chemicals (APD) trades at $303.44, up 1.17% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The stock shows strong analyst support with a consensus price target of $346, though high valuation ratios like a P/E of 30.86 and EV/EBITDA of 50.36 raise concerns. Recent news highlights a major semiconductor supply deal in Taiwan and raised guidance after Q3 2026 results.
The outlook is mixed: positive momentum from contract wins and earnings performance offers upside, but negative net income margins and elevated debt levels pose risks. Investors should weigh growth catalysts against financial leverage and profitability challenges.
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
